139 related articles for article (PubMed ID: 8541116)
1. Antibodies to LMP2A/2B in EBV-carrying malignancies.
Lennette ET; Winberg G; Yadav M; Enblad G; Klein G
Eur J Cancer; 1995 Oct; 31A(11):1875-8. PubMed ID: 8541116
[TBL] [Abstract][Full Text] [Related]
2. The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases.
Xu J; Ahmad A; Blagdon M; D'Addario M; Jones JF; Dolcetti R; Vaccher E; Prasad U; Menezes J
Int J Cancer; 1998 Oct; 79(5):481-6. PubMed ID: 9761116
[TBL] [Abstract][Full Text] [Related]
3. Detection and analysis of anti-latent membrane protein 2A antibodies in the sera of patients with Epstein-Barr virus associated malignancies.
Chen Y; Yao K; Sun H; Qing J; Peng GY
Chin Med J (Engl); 2005 May; 118(9):725-30. PubMed ID: 15899133
[TBL] [Abstract][Full Text] [Related]
4. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.
Khanna R; Burrows SR; Moss DJ; Silins SL
J Virol; 1996 Aug; 70(8):5357-62. PubMed ID: 8764046
[TBL] [Abstract][Full Text] [Related]
5. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases.
Meij P; Vervoort MB; Aarbiou J; van Dissel P; Brink A; Bloemena E; Meijer CJ; Middeldorp JM
J Infect Dis; 1999 May; 179(5):1108-15. PubMed ID: 10191211
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus gp350-specific antibody titers and antibody-dependent cellular cytotoxic effector function in different groups of patients: a study using cloned gp350-expressing transfected human T cell targets.
Khyatti M; Stefanescu I; Blagdon M; Menezes J
J Infect Dis; 1994 Dec; 170(6):1439-47. PubMed ID: 7995983
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of novel B-cell epitopes within EBV latent membrane protein 2 (LMP2).
Xue X; Zhu S; Li W; Chen J; Ou Q; Zheng M; Gong W; Zhang L
Viral Immunol; 2011 Jun; 24(3):227-36. PubMed ID: 21668364
[TBL] [Abstract][Full Text] [Related]
8. Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein-Barr virus infection.
Rechsteiner MP; Berger C; Zauner L; Sigrist JA; Weber M; Longnecker R; Bernasconi M; Nadal D
J Virol; 2008 Feb; 82(4):1739-47. PubMed ID: 18057232
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunoprecipitation in the diagnosis of chronic active Epstein-Barr virus infection.
Beauparlant P; Alfieri C; Joncas JH
J Med Virol; 1994 Mar; 42(3):241-6. PubMed ID: 8006636
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
Liu MT; Yeh CY
Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
[TBL] [Abstract][Full Text] [Related]
11. Antibody and antibody-dependent cellular cytotoxicity responses against the BamHI A rightward open-reading frame-1 protein of Epstein-Barr virus (EBV) in EBV-associated disorders.
Tanner JE; Wei MX; Alfieri C; Ahmad A; Taylor P; Ooka T; Menezes J
J Infect Dis; 1997 Jan; 175(1):38-46. PubMed ID: 8985194
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of multiple antibodies to Epstein-Barr virus as markers for detecting patients with nasopharyngeal carcinoma.
Liu MY; Chang YL; Ma J; Yang HL; Hsu MM; Chen CJ; Chen JY; Yang CS
J Med Virol; 1997 Jul; 52(3):262-9. PubMed ID: 9210034
[TBL] [Abstract][Full Text] [Related]
13. ELISA for the detection of serum and saliva IgA against the BMRFI gene product of Epstein-Barr virus.
Nadala EC; Tan TM; Wong HM; Ting RC
J Med Virol; 1996 Sep; 50(1):93-6. PubMed ID: 8890046
[TBL] [Abstract][Full Text] [Related]
14. Detection of transcripts initiated from two viral promoters (Cp and Wp) in Epstein-Barr virus-infected nasopharyngeal carcinoma cells and biopsies.
Chang Y; Sheen TS; Lu J; Huang YT; Chen JY; Yang CS; Tsai CH
Lab Invest; 1998 Jun; 78(6):715-26. PubMed ID: 9645762
[TBL] [Abstract][Full Text] [Related]
15. [Expression and significance of EBV LMP2A in nasopharyngeal cancer specimens].
Xu J; Yao K; Yu C; Chen X; Li B; Sun H; Zhou F
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2005 Jun; 19(11):484-7. PubMed ID: 16124641
[TBL] [Abstract][Full Text] [Related]
16. Analysis and significance of anti-latent membrane protein-1 antibodies in the sera of patients with EBV-associated diseases.
Xu J; Ahmad A; D'Addario M; Knafo L; Jones JF; Prasad U; Dolcetti R; Vaccher E; Menezes J
J Immunol; 2000 Mar; 164(5):2815-22. PubMed ID: 10679125
[TBL] [Abstract][Full Text] [Related]
17. Immunization of common marmosets with Epstein-Barr virus (EBV) envelope glycoprotein gp340: effect on viral shedding following EBV challenge.
Cox C; Naylor BA; Mackett M; Arrand JR; Griffin BE; Wedderburn N
J Med Virol; 1998 Aug; 55(4):255-61. PubMed ID: 9661832
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma.
Henle G; Henle W
Int J Cancer; 1976 Jan; 17(1):1-7. PubMed ID: 175020
[TBL] [Abstract][Full Text] [Related]
19. Immune response to different sequences of the EBNA I molecule in Epstein-Barr virus-related disorders and in autoimmune diseases.
Marchini B; Dolcher MP; Sabbatini A; Klein G; Migliorini P
J Autoimmun; 1994 Apr; 7(2):179-91. PubMed ID: 7518683
[TBL] [Abstract][Full Text] [Related]
20. Sequence polymorphisms between latent membrane proteins LMP1 and LMP2A do not correlate in EBV-associated reactive and malignant lympho-proliferations.
Berger C; Rothenberger S; Bachmann E; McQuain C; Nadal D; Knecht H
Int J Cancer; 1999 May; 81(3):371-5. PubMed ID: 10209951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
